Idec receives accelerated equity funding from Genentech, patent license from Xoma for anti-CD20 MAb.
Executive Summary
GENENTECH ACCELERATES FUNDING SCHEDULE FOR IDEC-C2B8 COLLABORATION in anticipation of positive interim results from a pivotal trial of the Idec anti-CD20 monoclonal antibody in non-Hodgkin's B-cell lymphoma. Idec will present results from the first 50 patients of a planned 150 patients in a Phase III trial of IDEC-C2B8 May 21 to the American Society of Clinical Oncology annual meeting in Philadelphia.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: